Drug Profile
Research programme: heat shock protein 90 binding drug conjugates - Tarveda Therapeutics
Alternative Names: HDC-docetaxel; HSP90-binding drug conjugates - Tarveda Therapeutics; STA-9183Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Synta Pharmaceuticals
- Developer Madrigal Pharmaceuticals
- Class Antineoplastics; Drug conjugates; Hormones; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Cancer in USA
- 26 Feb 2020 Heat shock protein 90 binding drug conjugates are still in preclinical development in Cancer in USA
- 28 Jan 2020 No recent reports of development identified for preclinical development in Cancer in USA